Specify a stock or a cryptocurrency in the search bar to get a summary
Advicenne
ALDVIAdvicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France. Address: 3ème étage 262, Paris, France, 75008
Analytics
WallStreet Target Price
6.74 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALDVI
Dividend Analytics ALDVI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALDVI
Stock Valuation ALDVI
Financials ALDVI
Results | 2019 | Dynamics |